Serbian drug maker Hemofarm, part of Germany's Stada Group, said it opened a quality control building in Vrsac, in northern Serbia, following a 6 million euro ($6.4 million) investment.
The building spans around 7,000 sq m and enables the best working conditions for 300 employees, Hemofarm said in a statement on Wednesday.
"We at Hemofarm work hard to increase our efficiency and sustainability, and the best example of that dedication is our newest investment – the quality building, which is synchronised with good manufacturer practice and the highest standards in the pharmaceutical industry," CEO Ronald Seeliger said at the opening ceremony, according to the statement.
In August, Serbian media reported that Stada Group had decided to set up a unit for Southeastern Europe (SEE) that will be led by Hemofarm. The unit will be responsible for business in Hungary, Slovenia, Croatia, Bosnia and Herzegovina, Serbia, Albania, Bulgaria and Romania.
Stada, which took over Hemofarm in 2006, has so far invested more than 200 million euro in the modernisation of equipment and production facilities of the Serbian company, as well as training of workers.
($ = 0.942599 euro)